Lipid-Lowering Effects of Ethyl 2-Phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in Rodents by Holub, Justin M. et al.
University of Richmond
UR Scholarship Repository
Chemistry Faculty Publications Chemistry
2004
Lipid-Lowering Effects of Ethyl
2-Phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in
Rodents
Justin M. Holub
Kathy O'Toole-Colin
Adam Getzel
Anthony Argenti
Michael A. Evans
See next page for additional authors
Follow this and additional works at: http://scholarship.richmond.edu/chemistry-faculty-
publications
Part of the Organic Chemistry Commons
This Article is brought to you for free and open access by the Chemistry at UR Scholarship Repository. It has been accepted for inclusion in Chemistry
Faculty Publications by an authorized administrator of UR Scholarship Repository. For more information, please contact
scholarshiprepository@richmond.edu.
Recommended Citation
Holub, Justin M., Kathy O'Toole-Colin, Adam Getzel, Anthony Argenti, Michael A. Evans, Daniel C. Smith, Gerard A. Dalglish,
Shahzad Rifat, Donna L. Wilson, Brett M. Taylor, Ulander Miott, Josephine Glersaye, Kam Suet Lam, Bryan J. Mccranor, Joshua D.
Berkowitz, Robert B. Miller, John R. Lukens, Keith Krumpe, John T. Gupton, and Bruce S. Burnham. "Lipid-Lowering Effects of Ethyl
2-Phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in Rodents." Molecules 9, no. 3 (2004): 134-157. doi:10.3390/90300134.
Authors
Justin M. Holub; Kathy O'Toole-Colin; Adam Getzel; Anthony Argenti; Michael A. Evans; Daniel C. Smith;
Gerard A. Dalglish; Shahzad Rifat; Donna L. Wilson; Brett M, Taylor; Ulander Miott; Josephine Glersaye;
Kam Suet Lam; Bryan J. McCranor; Joshua D. Berkowitz; Robert B. Miller; John R. Lukens; Keith Krumpe;
John T. Gupton; and Bruce S. Burnham
This article is available at UR Scholarship Repository: http://scholarship.richmond.edu/chemistry-faculty-publications/44
Molecules 2004, 9, 135-157 
molecules 
ISSN 1420-3049 
http://www.mdpi.org 
 
Lipid-Lowering Effects of Ethyl 2-Phenacyl-3-aryl-1H-pyrrole-
4-carboxylates in Rodents 
Justin M. Holub 1, Kathy O'Toole-Colin 1, Adam Getzel 1, Anthony Argenti 1, Michael A. Evans 1, 
Daniel C. Smith 1, Gerard A. Dalglish 1, Shahzad Rifat 1, Donna L. Wilson 1, Brett M. Taylor 1, 
Ulander Miott 1, Josephine Glersaye 1, Kam Suet Lam 1, Bryan J. McCranor 1, Joshua D. 
Berkowitz 1, Robert B. Miller 2, John R. Lukens 2, Keith Krumpe 3, John T. Gupton 2 and Bruce 
S. Burnham 1,* 
 
1 Department of Chemistry and Biochemistry, Rider University, 2083 Lawrenceville Rd., 
Lawrenceville, NJ 08648, U.S.A. 
2 Department of Chemistry, University of Richmond, Richmond, VA 23173, U.S.A. 
3 Department of Chemistry, UNC-Asheville, One University Heights, Asheville, NC 28801, U.S.A. 
 
* Author to whom correspondence should be addressed. Tel: +1 609-896-5207; fax: +1 609-895-5782; 
e-mail: bburnham@rider.edu 
 
Received: 23 January 2004; in revised form: 28 January 2004 / Accepted 29 January 2004 / 
Published: 28 February 2004 
 
 
Abstract - A series of substituted 2-phenacyl-3-phenyl-1H-pyrrole-4-carboxylates were 
prepared from substituted acetophenones in 6 steps. The final condensations between a 
chloroenal and an aminoketone were carried out under neutral conditions in parallel to yield 
the series listed below. Selected pyrrole derivatives proved to be potent hypolipidemic agents 
lowering serum triglyceride concentrations in CF-1 male mice after 14 days of I.P. 
administration. One agent orally lowered serum cholesterol in Sprague-Dawley male rats at 
2mg/kg/day after 14 days. The agents demonstrated a lowering of mouse serum LDL-
cholesterol levels and selected compounds showed an elevation of serum HDL-cholesterol 
levels. The cholesterol concentrations in the liver were raised while the cholesterol and 
triglyceride contents of the aorta were significantly lowered by the selected trisubstituted 
pyrrole. 
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Introduction 
In recent years, polysubstituted pyrroles have shown interesting biological properties. 2,4-
Disubstituted brominated pyrroles, which are brominated at positions 3 and 5 along with 2,3,4-
trisubstituted pyrroles have demonstrated potent cytotoxic activity in vitro against a variety of murine 
and human suspended and solid tumor models [1-4]. Also, pentasubstituted pyrroles have proven to be 
potent hypocholesterolemic agents through the inhibition of HMG-CoA reductase activity, a key 
enzyme in the de novo synthesis of cholesterol [5-11]. Two of these pyrroles, atorvastatin and 
fluvastatin (Figure 1), are in clinical use today for the treatment of hyperlipidemias [12]. It is not 
unprecedented for compounds to exhibit hypolipidemic in addition to other pharmacological 
properties. The HMG-CoA reductase inhibitors have recently demonstrated various pleiotropic effects 
including cardiovascular protective effects independent of hypercholesterolemia [11-13], anti-
inflammatory effects [14-16] and a decreased risk of the development of Alzheimer's disease [17-20]. 
Compactin, also an HMG-CoA reductase inhibitor, has been shown to inhibit the growth of murine 
L929 cells [21]. Likewise, a number of amine-boranes [22-28], 2,3-dihydrophthalazine-l,4-diones 
[29], sesquiterpene lactones [30], and 1,2,4-triazolidine-3,5-diones [31] have demonstrated such 
crossover between cytotoxic and hypolipidemic properties.  
 
Figure 1. Structures of the clinically used pyrrole-containing hypolipidemic agents 
atorvastatin (LipitorR) and fluvastatin (LescolR). 
 
 
 
 
 
 
 
 
 
 
 
 
Atorvastatin     Fluvastatin 
 
 
 
 
Given the importance of correcting hyperlipidemias to improve the risks of developing 
cardiovascular disease and the toxic effects of the HMG-CoA reductase inhibitors such as liver damage 
[12], the search for new lipid-lowering compounds is of interest. As part of our screening program 
evaluating the biological effects of pyrroles, we report the synthesis and preliminary lipid-lowering 
effects of 2,3,4-trisubstituted pyrroles in rodents. An initial examination of the structure and lipid-
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lowering profiles of these new pyrroles compared to the atorvastatin and fluvastatin shows that the 
2,3,4-trisubstituted pyrroles may represent a new class of hypolipidemic agents.  
 
Chemistry 
 
The regioselective synthesis of 2,3,4-trisubstituted pyrroles from chloroenals has recently been 
reported by Gupton, et. al [1-4,32,33]. The convergent synthesis generates acceptable yields through 
the final condensation, however with the aid of the XT reactor (Mettler-Toledo AutoChem), up to six 
derivatives were easily prepared under a dry, inert atmosphere and constant temperature. The yields 
reported represent the final recrystallized amounts of analytically pure compounds isolated for use in 
the bioassays and do not represent the overall chemical yields for the reactions.  
 
Figure 2: Preparation of the β-chloroenals from acetophenones 
 
 (R3 = 4'-Cl,  R4 = -CH2CH3  [a]; R3 = 4'-Br,  R4 = -CH2CH3  [b], R3 = 3'-Cl,  R4 = -CH2CH3  
[c], R3 = 4'-CH3,  R4 = -CH2CH3 [d], R3 = 4'-F,  R4 = -CH2CH3  [e]; R3 = 4'-OCH3 , R4 = -
CH3  [f]). 
 
Figure 3: Preparation of the salt of the α-aminoketones from 2-bromoacetophenones 
 
 
(R2 = 4'-Cl [g], 4'-H [h], 4'-F [i], 4'-OCH3 [j], 4'-CH3 [k]). 
 
The synthesis was initiated (Figure 2) with the condensation of the acetophenone enolate 17 with a 
dialkyl carbonate to provide the β-ketoester 18 in nearly quantitative yield. Formation of the 
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vinylogous amide 19 was carried out by condensation of the β-ketoester and N,N-dimethylformamide 
dimethyl acetal (DMFA) under neutral conditions. The vinylogous amide 19 was then quantitatively 
converted to the β-chloroenal 20 by reaction with thionyl chloride in THF followed by in situ 
hydrolysis. Condensation with an α-amino ketone 23 (Figure 3), formed from reaction of an 
α-bromoacetophenone 21 with sodium azide followed by triphenylphosphine reduction yielded the 
trisubstituted pyrroles (1-5, 7-12, Figure 4). The final condensations were carried out in the XT reactor 
under neutral conditions in dry DMF under dry nitrogen and at a constant temperature of 65oC.  
 
Figure 4: Synthesis of the 2,3,4-trisubstituted pyrroles [1-5, 7-12]. 
Results 
 
A series of 2,3,4-trisubstituted pyrroles was prepared (Table 1) and their lipid-lowering properties 
were assessed in mice and rats.  
 
Table 1: Substitutions on the pyrroles screened for in vivo hypolipidemic activity in rodents. 
Compound Ra- Rb- Rc- Rd- 
1 H- 4'-Cl-C6H4- 4'-Cl-C6H4- H3CH2COOC- 
2 H- C6H5- 4'-Br-C6H4- H3CH2COOC- 
3 H- C6H5- 3'-Cl-C6H4- H3CH2COOC- 
4 H- 4'-F-C6H4- 4'-CH3-C6H4- H3CH2COOC- 
5 H- 4'-Cl-C6H4- 4'-CH3-C6H4- H3CH2COOC- 
6 H3C- CH3CH2O- H- 4'-Cl-C6H4- 
7 H- 4'-F-C6H4- 4'-F-C6H4- H3CH2COOC- 
8 H- 4'-CH3O-C6H4- 4'-Cl-C6H4- H3CH2COOC- 
9 H- 4'-Cl-C6H4- 4'-F-C6H4- H3CH2COOC- 
10 H- 4'-CH3-C6H4- 4'-CH3O-C6H4- H3COOC- 
11 H- 4'-CH3O-C6H4- 4'-CH3O-C6H4- H3COOC- 
12 H- 4'-Cl-C6H4- 4'-CH3O-C6H4- H3COOC- 
13 H- 4'-CH3O-C6H4- 4'-CH3O-C6H4- 4'-CH3O-C6H4- 
14 H- CH3O- 3',4'-(CH3O)2-C6H4- 3',4'-(CH3O)2-C6H4- 
15 H3C- CH3CH2O- 3',4'-(CH3O)2-C6H4- 3',4'-(CH3O)2-C6H4- 
N
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Two of the pyrroles, compounds 1 and 2, were initially screened in rats at an oral dose of 2 
mg/kg/day for 14 days.  Compound 1 demonstrated a 32% reduction in the total serum cholesterol 
levels in the rats after 14 days; however, the same compound showed an elevation in the triglycerides 
of 47%. Compound 2 also demonstrated a 59% elevation in the serum triglyceride levels in rats but had 
no effect on total cholesterol levels (Table 2).  
 
Table 2: In Vivo Hypolipidemic Activity of the 2,3,4-trisubstituted pyrroles (1) and (2) in 
Sprague-Dawley Rats at 2 mg/kg/day orally for 14 days. 
 
Percent of Control  (X+SD) 
Day 7              Day 14 N=6 Compound 
(g/rat/day) 
Food Consumption 
Cholesterol Triglycerides Cholesterol Triglycerides
1 19.13     98+5   93+18   68+16* 147+7* 
2 20.60  120+24   85+13 104+7 159+8* 
Atorvastatina 19.03  110+14   92+28   69+6* 119+5* 
Gemfibrozilb 17.47  122+5  56+62* 116+17 138+2* 
Controlc 20.06  100+14d 100+7e 100+8f 100+6g 
a Dosed at 8 mg/kg/day  e 94 mg/dL serum triglycerides 
b Dosed at 90 mg/kg/day  f 46 mg/dL total serum cholesterol 
c 1% CMC   g 56 mg/dL serum triglycerides 
d 83 mg/dL total serum cholesterol * p < 0.005 (t-test)  
 
For the rat study, tissue samples of liver, small intestine, aorta and feces were taken, homogenized 
in sucrose/EDTA, the lipids extracted with methanol and chloroform and analyzed for cholesterol and 
triglyceride content (Table 3).  
 
 
Table 3: The effects of the 2,3,4-trisubstituted pyrroles (1) and (2) in Sprague-Dawley 
Rats at 2 mg/kg/day orally for 14 days on tissue lipid levels. 
 
N=6 Percent of Control (X+SD) 
Compound Cholesterol Triglycerides 
Liver  
1 187+19* 106+20 
2 197+19* 100+40 
Atorvastatina 169+19* 166+35 
Gemfibrozilb 107+18   96+16 
Controlc 100+24d 100+35e 
  
Small intestine  
1   48+13 127+24 
2   33+17 115+20 
Atorvastatina   49+15   55+18* 
Gemfibrozilb   75+16   81+28 
Controlc 100+35f 100+19g 
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Aorta  
1   61+12*   15+41* 
2 126+18   30+28* 
Atorvastatina 105+17   56+23* 
Gemfibrozilb 106+13   29+22* 
Controlc 100+15h 100+14i 
  
Feces  
1 123+18   84+20 
2   94+10   92+16 
Atorvastatina 178+54   85+16 
Gemfibrozilb 106+13   98+23 
Controlc 100+22j 100+24k 
a Dosed at 8 mg/kg/day g 12.78 mg/g (wt)  
b Dosed at 90 mg/kg/day h 2.97 mg/dL (wt) 
c 1% CMC I 13.85 mg/dL (wt) 
d 3.17 mg/g (wet tissue) j 7.92 mg/dL (wt) 
e 3.31 mg/dL (wt) k 9.44 mg/dL (wt) 
f 12.68 mg/dL (wt) * p < 0.005 (t-test) 
 
Both compounds 1 and 2 demonstrated an elevation in the cholesterol content of the liver by 87 and 
97%, respectively, without any effects on the triglyceride content. Both compounds 1 and 2 also 
reduced the cholesterol content of the small intestine by 52 and 67%, respectively and showed a slight 
elevation of 27 and 15%, respectively of the triglyceride content. Compounds 1 and 2 demonstrated a 
marked reduction on the triglyceride content of the aorta with compound 1 also demonstrating a 39% 
reduction in the cholesterol content. Neither compound demonstrated any significant effects on the 
lipid content of the feces although compound 1 elevated fecal cholesterol levels 23% which was not 
significantly different from the control. 
An expanded series of the pyrroles was subsequently tested in mice. The new agents demonstrated 
potent hypolipidemic effects in mice after 14 days of I.P. dosing at 8 mg/kg/day for compounds 3-12 
and 4 mg/kg/day for compounds 13-15 (Table 4). Compounds 3, 7, 13 and 14 lowered both serum 
cholesterol and triglyceride levels in mice by at least 24% and 33%, respectively. The most effective 
agent in the series was compound 14, which demonstrated cholesterol and triglyceride-lowering effects 
at both 7 and 14 day sampling points achieving a 34% reduction in total serum cholesterol and 38% 
reduction in serum triglyceride concentrations at 4 mg/kg/day. Compound 4 also demonstrated a 
cholesterol-lowering effect of 34%, but its triglyceride-lowering effects were not sustained after 14 
days. Compounds 6 and 15 demonstrated a slight cholesterol reduction of 18 and 11%, respectively. 
Compounds 8, 9, 10 and 12 demonstrated a reduction in serum triglyceride levels of 33 to 48% without 
any effects on the cholesterol levels. An analysis of the serum lipoprotein cholesterol levels, LDL-
cholesterol and HDL-cholesterol, showed a remarkable reduction in LDL-cholesterol of 61 to 35% in 
the mice dosed with compounds 7, 8, 9, 11, 12, 13 and 15 (Table 5). The HDL-cholesterol levels were 
concomitantly reduced in the mice by compounds 7, 8, 10 and 13 demonstrating a 54 to 18% 
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reduction. However, compounds 9, 12 and 15 produced an elevation of the mice HDL-cholesterol by 
183, 103 and 150%, respectively. Compound 14 also demonstrated a 48% increase in the mouse serum 
HDL-cholesterol. 
 
Table 4: In Vivo Hypolipidemic Activity of the substituted pyrroles (3-15) in CF-1 male 
mice at 8mg/kg/day, IP for 14 days. 
 
  Percent of Control (X+SD) 
N=6  Day 7  Day 14 
Compound                        Cholesterol Triglycerides Cholesterol Triglycerides
3    68+11*   28+29*   72+8*   59+37 
4    69+9*   54+5*   66+11* 113+43 
5    73+8*   99+8   87+8 184+28 
6    97+7   62+7*   82+9* 109+20 
7    67+15*   56+24*   76+14   61+30* 
8    79+14*   91+31   91+13   53+23* 
9    95+8   58+14*   91+18   52+23* 
10    93+10   70+19   98+17   60+21* 
11    89+9   76+26   90+17   77+30 
12  102+12*   67+11* 103+12   67+31 
13a    80+13*   49+17*   76+8*   65+28* 
14 a    62+19*   55+20*   66+14*   62+23* 
15 a    75+9*   83+14   89+3*   76+24 
Atorvastatinb    77+6*   66+11*   81+17   84+33 
Gemfibrozilc    62+11*   43+21*   57+13*   82+15 
Niacind    97+18   70+8   93+24  102+21 
Controle  100+14f  100+7g 100+8h  100+6i 
a Dosed at 4 mg/kg/day, IP f 188 mg/dL total serum cholesterol 
b Dosed at 8 mg/kg/day, IP g 231 mg/dL serum triglycerides 
c Dosed at 90 mg/kg/day, IP h 164 mg/dL total serum cholesterol 
d Dosed at 12.5 mg/kg/day, IP i 179 mg/dL serum triglycerides 
e 1% CMC, PO * p < 0.005 (t-test)  
 
Discussion 
 
Many of the 2,3,4-trisubstituted pyrroles in this series demonstrated potent lipid-lowering effects in 
mice at 4-8 mg/kg/day I.P. or rats at 2 mg/kg/day orally. While selected compounds 3, 7, 13 and 14 
showed a reduction in both the total serum cholesterol and triglyceride concentrations, the most 
profound effects were with the reduction in serum triglyceride levels by compounds 3, 7, 8, 9, 10, 12, 
13 and 14 (Table 4). The most effective lipid-lowering compound was compound 14 demonstrating an 
early and sustained reduction of both total serum cholesterol and triglycerides in addition to showing 
an elevation in the HDL-cholesterol, the lipoprotein fraction that offers protection against 
atherosclerosis development. Compound 14, which also contains the 3',4'-dimethoxyphenyl 
Molecules 2004, 9 
 
142
substituents has been previously synthesized [36] and employed as the precursor to the marine natural 
product Ningalin B (Figure 5). The related N-methyl Ningalin B precursor, 15, was much less active 
indicating that a free N-H functionality may be necessary for activity. In contrast to the active HMG- 
CoA reductase inhibitors, such as atorvastatin and fluvastatin, which are pentasubstituted pyrroles, 
most of the active pyrroles contain a free N-H functionality. Likewise, since none of the compounds 
studied contained a 3,5-dihydroxyheptanoate group, it is postulated that these compounds do not 
inhibit the activity of HMG CoA reductase. A common feature between the active compounds 
presented here and the statins is at least one 4'-halo- (-Cl or -F) or 4'-methoxyphenyl group. In fact, the 
next best agent in this study was compound 7, which has 4'-fluorophenyl groups in both the 3 and 4 
positions of the pyrrole ring.  
 
Figure 5: Structure of the marine natural product Ningalin B. 
 
Table 5: In Vivo Hypolipidemic Activity of the substituted pyrroles (3-15) in CF-1 male 
mice at 8mg/kg/day, IP for 14 days. 
 
N=6 Percent of Control (X+SD) 
   Compound LDL-Cholesterol HDL-Cholesterol 
3    - 102+20  
4    -   112+24 
5    -   109+21 
6    - 130+12 
7   47+21*     63+53 
8   65+40*   56+38 
9   53+31   283+10* 
10 106+5   46+31* 
11   47+15*   96+63 
12   47+25*   203+21 
13a   39+34*   82+31 
14a 114+21   148+4 
N
OH
OH
HO
HO
OH
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O
O
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15a 156+17   250+11 
Atorvastatinb    - 178+34 
Gemfibrozilc    - 192+8* 
Niacind    -   152+19 
Controle 100+15f    100+14g   
a Dosed at 4 mg/kg/day, IP e 1% CMC, PO 
b Dosed at 8 mg/kg/day, IP f 86 mg/dL LDL-Cholesterol 
c Dosed at 90 mg/kg/day, IP g 63 mg/dL HDL-Cholesterol 
d Dosed at 12.5 mg/kg/day, IP * p < 0.005 (t-test) 
 
But while compound 7 showed a reduction in LDL-cholesterol levels, it also showed a reduction in 
HDL-cholesterol levels. For compounds, 9 and 12 which showed the desired lipoprotein modulations 
(e.g., a reduction in LDL-cholesterol with a concomitant elevation in the HDL-cholesterol) only the 
serum triglyceride levels, were significantly reduced. Compounds 9 and 12 also fit the pattern of 4'-
halo- or 4'-methoxyphenyl groups in positions 3 and 4 of the pyrrole ring. In the orally dosed rats, 
compound 1, containing a 4'-chlorophenyl group in the 3 and 4 positions, demonstrated cholesterol-
lowering effects in the serum at 2 mg/kg/day. However, compound 1 showed an elevation in the serum 
triglyceride levels in contrast to the effects observed with structurally similar compounds in the mouse 
study. Fecal elimination of cholesterol or triglycerides did not appear to be involved in the lipid-
lowering effect of compound 1. The reduction of the cholesterol and triglyceride content of the aorta 
by compound 1 is a favorable response in relation to the development of atherosclerosis and 
cardiovascular disease. Like atorvastatin, compounds 1 and 2 also demonstrated an increase in the 
cholesterol content of the liver indicating that some effect on cholesterol metabolism is occurring due 
to the administration of compounds 1 and 2. The reduction in the cholesterol content of the small 
intestine by compounds 1 and 2 also suggests that an effect on cholesterol metabolism had occurred 
since the fecal elimination of cholesterol was not observed. Fecal elimination was not evident on day 
14, but for compound 1, a 23% increase was present which may reflect a trend in fecal elimination. 
 
Conclusions 
 
A series of 2,3,4-trisubstituted pyrroles was synthesized and selected agents demonstrated potent 
hypolipidemic activity in mice and rats at 2-8 mg/kg/day lowering the total serum cholesterol and 
triglycerides levels. The pyrroles overall demonstrated more of an effect in reducing triglycerides than 
reducing cholesterol. Selected agents also showed a reduction in LDL-cholesterol along with an 
elevation in HDL-cholesterol. The magnitude of the total serum cholesterol reduction, HDL-
cholesterol elevation and the modulations of the cholesterol content of the liver and small intestine 
demonstrate similarities between compound 1 and atorvastatin, the standard HMG-CoA reductase 
inhibitor. However, many of the pyrroles were more effective as hypotriglyceridemic agents than 
atorvastatin. These observations and the fact that these pyrroles are not fully substituted nor contain the 
3,5-dihydroxyheptanoate side chain, lead to the conclusion that the trisubstituted pyrrole do not exert 
their lipid-lowering effects via the inhibition of HMG-CoA reductase activity.  
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The most active pyrrole derivatives contain some of the structural similarities to atorvastatin and 
fluvastatin including a 4'-halophenyl substituents and a carbonyl-containing substituent, but differ in 
that they do not contain the dihydroxyheptanoate group. The statins also show interesting metabolic 
effects outside that of the inhibition of HMG-CoA reductase activity. Therefore, these 2,3,4-
trisubstituted pyrroles may represent a new class of lipid-lowering agents. 
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Experimental 
 
General:  
 
All chemicals and reagents were obtained from Sigma-Aldrich Chemical Company (Milwaukee, 
WI) and used as received. Solvents were stored over 4A molecular sieves and used as received, except 
for dry solvents, which were dried and distilled using standard procedures [34]. TLC was performed 
using silica gel 60F 254 plates (silica gel on plastic, Aldrich Chemical Company). Melting points were 
obtained on a Thomas-Hoover Uni-melt apparatus (capillary method), and were uncorrected. All 
boiling points were obtained under reduced pressure and noted at the temperature of first moisture 
deposit in receiving flask. IR spectra were obtained on a Perkin-Elmer 1600 FTIR spectrometer on 
sodium chloride plates or in a potassium chloride liquid cell in CHCl3 or CDCl3. NMR spectra were 
obtained on a 300 MHz Bruker Avance FT-NMR spectrometer. Unless stated otherwise CDCl3 and 
tetramethylsilane were used as solvent and external standard (δ = 0 ppm), respectively, for 1H and 13C 
spectra. Elemental analyses were performed by Quantitative Technologies, Inc. (Whitehouse, NJ). 
SFC/MS was on a Berger SFC/MS apparatus fitted with a Waters ZQ mass detector using a pyridine 
gradient (Berger Instruments, Inc., Newark, DE). HRMS-CI was performed by the University of 
Minnesota Mass Spectrometry Service Laboratory (Minneapolis, MN). 
 
Chemistry 
 
General Preparation of the β-ketoesters 18a-f: Four eq of NaH, as a 60% mineral oil dispersion, were 
placed in a round bottom flask under N2 and washed with hexanes (3 x 50 mL), then toluene (150 mL) 
and 5 eq of the dialkyl carbonate were added. To the resulting suspension, 1 eq of acetophenone was 
slowly added over 1 hr with stirring at rt. The solution was then stirred at reflux overnight. The 
resulting mixture was cooled to rt. and glacial acetic acid (35 mL) was added and this was followed by 
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dilution with a solution of of conc. HCl (20 mL) in ice water (150 mL). The aqueous solution was 
extracted with ethyl acetate  (3 X 75mL). The organic layers were neutralized by extraction with sat. 
NaHCO3 and dried over sodium sulfate. The volatiles were then removed under reduced pressure. The 
crude oil was purified by Kugelrohr distillation. 
 
Ethyl 3-(4'-Chlorophenyl)-3-oxopropionate (18a)[1]. Obtained from 4'-chloroacetophenone and diethyl 
carbonate as a clear oil (54%); bp = 121-123oC at 0.5 mmHg 1H-NMR δ = 7.81 (2H, d, J = 8.2 Hz), 
7.37 (2H, d, J = 8.2 Hz), 4.13 (2H, q, J = 7.2 Hz), 3.88 (2H, s), 1.18 (3H, t,  J = 7.2 Hz) ppm; 13C-
NMR δ = 192, 168, 141, 132, 130.3, 129.5, 62, 46, 15 ppm (C11H11ClO3).  
 
Ethyl 3-(4'-Bromophenyl)-3-oxopropionate (18b)[1]. Obtained from 4'-bromoacetophenone and diethyl 
carbonate as a clear oil (82%); bp = 129-131oC at 0.6 mmHg 1H-NMR δ = 7.76 (2H, d, J = 8.5 Hz), 
7.76 (2H, d, J = 8.5 Hz), 4.08 (2H, q, J = 7.2 Hz), 3.82 (2H, s), 1.13 (3H, t, J = 7.2 Hz) ppm; 13C-NMR 
δ = 191, 167, 140, 135, 131, 129, 62, 46, 14 ppm (C11H11BrO3). 
 
Ethyl 3-(3'-Chlorophenyl)-3-oxopropionate (18c)[1]. Obtained from 3'-chloroacetophenone and diethyl 
carbonate as a clear oil (47%); bp = 114-116oC at 0.5 mmHg 1H-NMR δ = 7.83 (1H, s), 7.02-7.75 (3H, 
m), 4.11 (2H, q, J = 7.2 Hz), 3.85 (2H, s), 1.22 (3H, t, J = 7.2 Hz) ppm; 13C-NMR δ = 192, 167, 138, 
136, 134, 131, 129, 127, 62, 46, 14 ppm (C11H11ClO3). 
 
Ethyl 3-(4'-Methylphenyl)-3-oxopropionate (18d) [1]. Obtained from 4'-methylacetophenone and 
diethyl carbonate as a clear oil (58%); bp =139oC at 0.2 mmHg; 1H-NMR δ = 7.81 (2H, d,  J = 8.1 Hz), 
7.23 (2H, d, J = 8.1 Hz), 4.18 (2H, q, J = 7.2 Hz), 3.91 (2H, s), 2.38 (3H, s), 1.23 (3H, t, J = 7.2 Hz) 
ppm; 13C-NMR δ = 192, 167, 144, 134, 130, 129, 62, 46, 22, 14 ppm (C12H14O3). 
 
Ethyl 3-(4'-Fluorophenyl)-3-oxopropionate (18e). Obtained from 4'-fluoroacetophenone and diethyl 
carbonate as a clear oil (100%); 1H-NMR δ = 7.98 (2H, d of d, JH,F = 5.3 Hz, JH,H = 8.8 Hz), 7.14 (2H, 
t, J = 8.8 Hz), 4.21 (2H, q, J =7.2 Hz), 3.97 (2H, s), 1.25 (3H, t, J = 7.2 Hz); 13C-NMR δ = 191.07, 
191.03, [167.38, 164.44 (d, JC,F = 256 Hz)], 167.39, 131.39, 115.86, 61.55, 45.96, 14.09 
ppm (C11H11FO3). 
 
Methyl 3-(4'-Methoxyphenyl)-3-oxopropionate (18f). Obtained from 4'-methoxyacetophenone and 
dimethyl carbonate as a clear oil (77%); bp = 154-156oC at 1.2 mmHg; 1H-NMR δ = 7.87 (2H, d, J= 9 
Hz), 7.43 (2H, d, J= 9 Hz), 3.98 (3H, s), 3.79 (2H, s), 3.73 (3H, s); 13C-NMR δ = 191.20, 168.48, 
164.29, 131.14, 129.31, 114.24, 55.76, 52.51, 45.63 ppm (C11H12O4). 
 
General Preparation of the Vinylogous Amides 19: To 1 eq of the β-ketoester in dry DMF (100mL) 
was added 3.5 eq of N,N-dimethylformamide dimethylacetal (DMFA). The solution was refluxed 
overnight then cooled to room temperature and the DMF was removed via Kugelrohr distillation. The 
yields were quantitative and the dark oils were used without further purification. 
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Ethyl 1-(4'-Chlorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate (19a) [1]. Obtained from 
ethyl 3-(4'-chlorophenyl)-3-oxopropionate (18a) as a dark brown oil (93%); 1H-NMR of Z isomer δ = 
7.53-7.76 (3H, m), 7.29 (2H, d, J = 8.7 Hz), 3.90 (2H, q, J = 7.2 Hz), 2.92 (6H, br s), 0.88 (3H, t, J = 
7.2 Hz) ppm; 13C-NMR of Z isomer δ = 192.91, 168.79, 156.61, 130.61, 130.46, 129.92, 128.58, 
128.17, 60.19, 14.34 ppm (C14H16ClNO3). 
 
Ethyl 1-(4'-Bromophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate (19b)[1]. Obtained from 
ethyl 3-(4'-bromophenyl)-3-oxopropionate (18b) as a dark brown oil (66%); 1H-NMR of Z isomer δ = 
7.66 (1H, s), 7.56 (2H, d, J = 8.4 Hz), 7.45 (2H, d, J = 8.4 Hz), 3.90 (2H, q, J = 7.2 Hz), 2.88 (6H, br 
s), 0.87 (3H, t, J = 7.2 Hz) ppm; 13C-NMR of Z isomer δ = 191.65, 167.42, 161.49, 155.31, 131.10, 
130.68, 130.14, 129.79, 128.81, 58.80, 12.92 ppm (C14H16BrNO3). 
 
Ethyl 1-(3'-Chlorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate (19c)[1]. Obtained from 
ethyl 3-(3'-chlorophenyl)-3-oxopropionate (18c) as a dark brown oil (68%); 1H-NMR of Z isomer δ = 
7.92 (1H, s), 7.30-7.82 (4H, m), 4.21 (2H, q, J = 7.2 Hz), 3.03 (6H, br s), 1.25 (3H, t, J = 7.2 Hz) ppm; 
13C-NMR of Z isomer δ = 191.70, 167.48, 163.37, 157.09, 130.49, 129.72, 129.64, 129.61, 128.95, 
127.76, 127.02, 62.04, 14.45 ppm (C14H16ClNO3). 
 
Ethyl 1-(4'-Methylphenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate (19d)[1]. Obtained from 
ethyl 3-(4'-methylphenyl)-3-oxopropionate (18d) as a dark brown oil (85%); bp=138-143oC at 3 
mmHg; 1H-NMR of Z isomer δ = 7.93, (1H, s), 7.58 (2H, d, J = 8.1 Hz), 7.10 (2H, d, J = 8.1 Hz), 3.90 
(2H, q, J = 7.1 Hz), 2.86 (6H, br s), 2.30 (3H, s), 0.87 (3H, t, J = 7.1 Hz) ppm; 13C-NMR of Z isomer δ 
= 194, 169, 155, 142, 139, 129.3, 129.0, 126, 60, 44, 22, 14 ppm (C15H19NO3). 
 
Ethyl 1-(4'-Fluorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate (19e). Obtained from ethyl 
3-(4'-fluorophenyl)-3-oxopropionate (18e) as a dark brown oil (74%); 1H-NMR δ = 7.79 (2H, br. s) 
7.70 (1H, s) 7.05 (2H, t, J= 9 Hz), 3.96 (2H, q, J= 7 Hz), 2.96 (6H, br. s), .925 (3H, t, J= 7 Hz) 
(C14H16FNO3). 
 
Methyl 1-(4'-Methoxyphenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate (19f). Obtained from 
methyl 3-(4'-methoxyphenyl)-3-oxopropionate (18f) as a dark brown oil (81%); 1H-NMR of Z isomer 
δ = 7.75 (2H, br. s), 7.60 (1H, br. s), 6.82 (2H, d, J= 9 Hz), 3.78 (3H, s), 3.46 (3H, s), 2.86 (6H, br. s) 
(C14H17NO4). 
 
General Preparation of the β-Chloroenals 20: To the vinylogous amide in dry THF (300 mL) was 
slowly added 3.5 eq of thionyl chloride. The reaction was brought to 50oC for 4 hours. dH2O (200 mL) 
was very slowly added and the reaction and heated to 50oC for 2-3 hrs. The solution was cooled to rt. 
and extracted with ethyl acetate (3 x 100mL). The organic layers were dried over sodium sulfate and 
the volatiles were removed under reduced pressure. The reaction afforded a mixture of E and Z 
isomers. NMR data was recorded for the major isomer. 
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Ethyl 3-(4'-Chlorophenyl)-3-chloropropenal-2-carboxylate (20a) [1]. Obtained from ethyl 1-(4'-
chlorophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate  (19a) as a pale yellow oil (51%); bp = 
132-134oC at 0.35 mmHg; 1H-NMR of Z isomer δ = 9.28 (1H, s), 7.42 (2H, d, J = 8.8 Hz), 7.32 (2H, d, 
J = 8.8 Hz), 4.31 (2H, q, J = 7.2 Hz), 1.29 (3H, t, J = 7.2 Hz) ppm; 13C-NMR of Z isomer δ = 186.07, 
164.00, 153.88, 138.73, 136.34, 132.54, 131.54, 131.53, 129.61, 62.77, 14.45 ppm (C12H10Cl2O3). 
 
Ethyl 3-(4'-Bromophenyl)-3-chloropropenal-2-carboxylate (20b) [1]. Obtained from ethyl 1-(4'-
bromophenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate  (19b) as a pale yellow oil (22%); bp = 
138-140oC at 0.35 mmHg; 1H-NMR of Z isomer δ = 9.28 (1H, s), 7.54 (2H, d, J = 8.7 Hz), 7.30 (2H, d, 
J = 8.7 Hz), 4.31 (2H, q, J = 7.2 Hz), 1.28 (3H, t, J = 7.2 Hz) ppm; 13C-NMR of Z isomer δ = 187.21, 
165.14, 155.09, 137.49, 134.18, 133.76, 132.83, 128.26, 63.92, 15.63 ppm (C12H10BrClO3). 
 
Ethyl 3-(3'-Chlorophenyl)-3-chloropropenal-2-carboxylate (20c) [1]. Obtained from ethyl 1-(3'-chloro-
phenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate  (19c) as a pale yellow oil (34%); bp = 134oC 
at 0.3 mmHg; 1H-NMR of Z isomer δ = 10.07 (1H, s), 7.84 (1H, s), 7.74 (1H, d, J = 7.7 Hz), 7.25-7.41 
(2H, m), 4.14 (2H, q, J = 7.2 Hz), 1.18 (3H, t, J = 7.2 Hz) ppm; 13C-NMR of Z isomer δ = 187.62, 
167.50, 137.90, 135.56, 134.06, 131.51, 130.50, 128.95, 128.39, 127.02, 62.04, 14.44 ppm 
(C12H10Cl2O3). 
 
Ethyl 3-(4'-Methylphenyl)-3-chloropropenal-2-carboxylate (20d) [1]. Obtained from ethyl 1-(4'-
methylphenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate  (19d) as a pale yellow oil (14%); bp = 
122-123oC at 0.3 mmHg; 1H-NMR of Z isomer δ = 9.40 (1H, s), 7.43 (2H, d, J = 8.1 Hz), 7.29 (2H, d, 
J = 8.1 Hz), 4.41 (2H, q, J = 7.2 Hz), 2.44 (3H, s), 1.40 (3H, t, J = 7.2 Hz) ppm; 13C-NMR of Z isomer  
δ = 186.48, 164.24, 155.46, 142.94, 135.83, 131.55, 130.29, 129.80, 62.40, 21.70, 14.37 ppm 
(C13H13ClO3). 
 
Ethyl 3-(4'-Fluorophenyl)-3-chloropropenal-2-carboxylate (20e). Obtained from ethyl 1-(4'-fluoro-
phenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate (19e) as a clear oil (100%); 1H-NMR of Z 
isomer δ = 10.0 (1H, s), 7.47 (2H, m), 7.02 (2H, t, J= 9 Hz), 4.02 (2H, q, J =7Hz), .98 (3H, t, J =7Hz) 
(C12H10ClFO3). 
 
Methyl 3-(4'-Methoxyphenyl)-3-chloropropenal-2-carboxylate (20f). Obtained from methyl 1-(4'-
methoxyphenyl)-3-(dimethylamino)prop-2-enone-2-carboxylate  (19f) as a pale yellow oil (100%); 
1H-NMR of Z isomer δ = 9.29 (1H, s), 7.39 (2H, d, J =9 Hz), 6.89 (2H, d, J= 9 Hz), 3.81 (3H, s), 3.78 
(3H, s) (C12H11ClO4). 
 
General Preparation of the α-Azidoacetophenones 22: To an α-bromoacetophenone in DMSO (50 
mL) was added 4 eq of sodium azide. The solution was stirred at rt. for 20-30 min., then poured into 
cold dH2O (100mL) and extracted with ethyl acetate (3 x 50mL). The combined organic layers were 
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dried over sodium sulfate. The solution was then slowly evaporated under reduced pressure and the 
crystals filtered from the concentrated ethyl acetate solution.  
 
2-Azido-4’-chloroacteophenone (22g) [1]. Obtained from 2-bromo-4'-chloroacetophenone (21g) as 
pale yellow needles (72%); mp = 68-69oC; 1H-NMR δ = 7.83 (2H, d, J = 8.3 Hz), 7.46 (2H, d, J = 8.3 
Hz), 4.41 (2H, s) ppm; 13C-NMR δ = 192.10, 140.80, 133.06, 129.46, 129.43, 54.97 ppm 
(C8H6ClN3O). 
 
2-Azido-4’-fluoroacteophenone (22i). Obtained from 2-bromo-4'-fluoroacetophenone (21i) as pale 
yellow needles; mp = 45oC; 1H-NMR δ = 8.0 (2H, d, J= 8 Hz), 7.0 (2H, d, J= 8 Hz), 4.61 (2H, s), 3.99 
(3H, s) (C8H6FN3O). 
 
2-Azido-4’-methoxyacteophenone (22j). Obtained from 2-bromo-4'-methoxyacetophenone (21j) as 
white needles (52%); mp = 71-73oC; 1H-NMR  δ = 7.99 (2H, d, J = 9 Hz), 7.10 (2H, d, J= 9 Hz),  4.61 
(2H, s), 3.99 (3H, s); 13C-NMR δ = 192.05, 164.59, 130.58, 127.73, 114.69, 56.04, 55.88 ppm 
(C9H9N3O2). 
 
2-Azido-4’-methylacteophenone (22k). Obtained from 2-bromo-4'-methylacetophenone (21k) as pale 
yellow needles (47%); mp = 71oC; 1H-NMR δ = 7.81 (2H, d, J = 8.2 Hz), 7.29 (2H, d, J = 8.2 Hz),  
4.53 (2H, s), 2.43 (3H, s); 13C-NMR δ = 192.72, 145.17, 132.00, 129.62, 128.06, 54.80, 21.76 ppm 
(C9H9N3O). 
 
General Preparation of the α−Aminoacteophenone PTSA Salts 23: To the α-azidoacetophenone in 
THF (100 mL) was added 1eq of triphenylphosphine and 3 eq of pTSA. The solution was stirred at rt. 
over night. The resulting white solid was filtered and washed with cold THF.  
 
2-Ammonium-4’-chloroacetophenone toulenesulfonate (23g) [1]. Obtained from 2-azido-4'-chloro-
acetophenone  (22g) as a white solid (81%); mp = 232-233oC; 1H-NMR (DMSO-d6): δ = 8.20 (3H, br 
s), 7.99 (2H, d, J = 8.7 Hz), 7.64 (2H, d, J = 8.7 Hz) 7.50 (2H, d, J = 8.1 Hz), 7.11 (2H, d, J = 8.1 Hz), 
4.53 (2H, s), 2.28 (3H, s) ppm; 13C-NMR δ = 192.22, 145.40, 139.90, 138.42, 132.70, 130.33, 129.49, 
128.45, 125.85, 45.30, 21.02 ppm (C15H16ClNO4S). 
 
2-Ammonium-4’-fluoroacetophenone toulenesulfonate (23i). Obtained from 2-azido-4'-fluoro-
acetophenone  (22i) as a white solid (76%); mp = 232oC; 1H-NMR (DMSO-d6): δ = 8.12 (3H, br s), 
8.00 (2H, d of d, JH,F  = 5.5 Hz, JH,H  = 9.2 Hz), 7.37 (2H, d, J = 8.1 Hz), 7.33 (2H, t, J = 8.9 Hz), 7.00 
(2H, d, J = 8.1 Hz), 4.50 (2H, s), 2.18 (3H, s); 13C-NMR δ = 192.04, [146.11, 137.92 (d, JC,F  = 618 
Hz)] , 131.78, 131.65, 130.85, 128.38, 125.84, 116.66, 116.36, 45.21, 21.12 ppm (C15H16FNO4S). 
 
2-Ammonium-4’-methoxyacetophenone toulenesulfonate (23j). Obtained from 2-azido-4'-
methoxyacetophenone  (22j) as a white solid (68%); mp = 188-189oC; 1H-NMR (DMSO-d6): δ = 8.16 
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(3H, br s), 8.00 (2H, d, J= 8 Hz), 7.47 (2H, d, J= 8 Hz), 7.11 (4H, d, J= 8 Hz), 4.54 (2H, br s), 3.87 
(3H, s), 2.28 (3H, s); 13C-NMR δ = 191.57, 164.50, 146.09, 137.92, 130.98, 128.38, 126.90, 125.83, 
114.61, 56.10, 44.85, 21.12 ppm (C16H19NO5S). 
 
2-Ammonium-4’-methylacetophenone toulenesulfonate (23k). Obtained from 2-azido-4'-methyl-
acetophenone  (22k) as a white solid (71%); mp = 189-191oC; 1H-NMR (DMSO-d6): δ = 8.09 (3H, br 
s), 7.81 (2H, d, J = 8.1 Hz), 7.37 (2H, d, J= 8.1 Hz), 7.29 (2H, d, J = 8.1 Hz), 7.00 (2H, d, J = 8.1 Hz), 
4.46 (2H, s), 2.30 (3H, s),  2.18 (3H, s); 13C-NMR δ = 192.80, 146.04, 145.58, 137.96, 131.58, 129.89, 
128.62, 128.39, 125.84, 45.11, 21.63, 21.12 ppm (C16H19NO4S). 
 
General Preparation of the 2-phenacyl-3-phenyl-1H-pyrrole-4-carboxylates 1-15: To the appropriate 
β-chloroenal in dry DMF (30 mL) was added 1.0 eq of the α-aminoacetophenone salt. The solution 
was stirred at 65oC for 2 days. The reaction was allowed to cool to rt.. The reaction mixture was added 
to dH2O (50 mL) and the resulting suspension extracted with ethyl acetate (2 x 50mL). The combined 
organic layers were dried over sodium sulfate then evaporated under reduced pressure. If the product 
could not be crystallized from hexanes:ethyl acetate it was purified by flash chromatography (silica 
gel) with a hexanes:ethyl acetate gradient.  The final product was recrystallized from hexanes:ethyl 
acetate. 
 
Ethyl 2-(4’-Chlorophenacyl)-3-(4’-chlorophenyl)-1H-pyrrole-4-carboxylate (1) [1]. Obtained from 2-
ammonium-4’-chloroacetophenone toluenesulfonate (23g) and ethyl 3-(4'-chlorophenyl)-3-
chloropropenal-2-carboxylate (20a) as tan crystals (4%); mp = 164-167oC; 1H-NMR  δ = 9.69 (1H, br 
s), 7.73 (1H, d, J = 3.4 Hz), 7.24 (2H, d, J = 6.7 Hz), 7.04 (2H, d, J = 6.1 Hz), 7.00 (2H, d, J = 6.7 Hz), 
6.98 (2H, d, J = 6.1 Hz), 4.17 (2H, q, J = 7.2 Hz), 1.18 (3H, t, J = 7.2 Hz) ppm; 13C-NMR δ = 186.48, 
163.74, 138.37, 135.83, 134.09, 132.73, 132.08, 131.88, 130.44, 130.03, 128.92, 128.21, 127.66, 
117.64, 60.36, 14.43 ppm. Anal. calcd for C20H15Cl2NO3: C, 61.87; H, 3.89; N, 3.61. Found: C, 61.94; 
H, 3.68; N, 3.47. 
 
Ethyl 2-(Phenacyl)-3-(4’-bromophenyl)-1H-pyrrole-4-carboxylate (2) [1]. Obtained from 2-amino-
acetophenone hydrochloride (23h) and ethyl 3-(4'-bromophenyl)-3-chloropropenal-2-carboxylate (20b) 
as tan crystals (17%); mp = 152-154oC; 1H-NMR δ = 9.72 (1H, br s), 7.69 (1H, d, J = 3.4 Hz), 7.24 
(2H, d, J = 7.4 Hz), 7.21 (2H, d, J = 7.4 Hz), 7.07 (2H, m, J = 8.5 Hz), 6.99 (2H, t, J = 7.4 Hz), 6.86 
(2H, d, J = 8.5 Hz), 4.11 (2H, q, J = 7.2 Hz), 1.14 (3H t, J = 7.2 Hz) ppm;  13C-NMR δ = 187.98, 
163.97, 137.34, 133.07, 132.42, 132.15, 131.86, 130.48, 130.12, 129.13, 128.91, 128.00, 121.86, 
117.23, 60.45, 14.56 ppm. Anal calcd for C20H16BrNO3: C, 60.32; H, 4.05; N, 3.52. Found: C, 60.03; 
H, 3.82; N, 3.55.   
 
Ethyl 2-(Phenacyl)-3-(3’-chlorophenyl)-1H-pyrrole-4-carboxylate (3) [1]. Obtained from 2-amino-
acetophenone hydrochloride (23h) and ethyl 3-(3'-chlorophenyl)-3-chloropropenal-2-carboxylate (20c) 
as pale yellow crystals (6%); mp = 135-137oC; 1H-NMR δ = 9.95 (1H, br s), 7.73 (1H, d, J = 3.6 Hz), 
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7.32 (2H, d, J = 8.1 Hz), 7.23 (2H, t, J = 7.5 Hz), 6.99-7.11 (4H, m), 6.88-6.98 (2H, m), 4.15 (2H, q, J 
= 7.2 Hz), 1.16 (3H, t, J = 7.2 Hz) ppm; 13C-NMR δ = 187.98, 163.90, 137.60, 135.47, 133.27, 131.67, 
130.28, 129.66, 129.01, 128.93, 128.86, 128.45, 127.97, 127.89, 127.42, 117.62, 60.32, 14.35 ppm. 
Anal calcd for C20H16ClNO3: C, 67.90; H, 4.56; N, 3.96. Found: C, 67.82; H, 4.46; N, 3.94. 
 
Ethyl 2-(4’-Fluorophenacyl)-3-(4’-methylphenyl)-1H-pyrrole-4-carboxylate (4). Obtained from 2-
ammonium-4’-fluoroacetophenone toluenesulfonate (23i) and ethyl 3-(4'-methylphenyl)-3-chloro-
propenal-2-carboxylate (20d) as a white solid (18%); mp = 112-115oC; 1H-NMR δ =  9.61 (1H, br s), 
7.64 (1H, d, J = 4Hz), 7.26 (2H, d of d, JH,F = 5 Hz, JH,H = 9 Hz), 6.87 (2H, d, J = 9 Hz), 6.77 (2H, d, J 
= 9 Hz), 6.59 (2H, t, J = 9 Hz), 4.09 (2H, q, J = 7 Hz), 2.16 (3H, s), 1.11 (3H, t, J = 7 Hz); 13C-NMR δ 
= 164.00, 137.37, 131.43, 131.61, 13172, 130.51, 130.01, 129.51, 128.70, 128.12, 117.14, 117.56, 
115.30, 115.26, 114.88, 114.58, 60.16, 21.29, 14.43 ppm. Anal calcd for C21H18FNO3: C, 71.78; H, 
5.16; N, 3.99. Found: C, 71.57; H, 5.21; N, 4.11. 
 
Ethyl 2-(4’-Chlorophenacyl)-3-(4’-methylphenyl)-1H-pyrrole-4-carboxylate (5) [1]. The title 
compound was obtained from 2-ammonium-4’-chloroacetophenone toluenesulfonate (23g) and ethyl 
3-(4'-methylphenyl)-3-chloropropenal-2-carboxylate (20d) as white crystals (15%); mp = 155-157oC; 
1H-NMR δ = 9.66 (1H, br s), 7.64 (1H, d, J = 3.6 Hz), 7.14 (2H, d, J = 8.7 Hz), 6.88 (2H, d, J = 8.7 
Hz), 6.84 (2H, d, J = 8.0 Hz), 6.77 (2H, d, J = 8.0 Hz), 4.09 (2H, q, J = 7.2 Hz), 2.18 (3H, s), 1.11 (3H, 
t, J = 7.2 Hz) ppm; 13C-NMR δ = 186.83, 163.94, 137.74, 137.57, 136.05, 133.88, 131.38, 130.45, 
130.25, 130.02, 128.90, 128.13, 127.93, 117.60, 60.19, 21.30, 14.44 ppm. Anal calcd for 
C21H18ClNO3: C, 68.57; H, 4.93; N, 3.81. Found: C, 68.25; H, 4.81; N, 3.77. 
 
Ethyl N-Methyl-4-(4’-chlorophenyl)-pyrrole-2-carboxylate (6) [35]. The 2-(4'-chlorophenyl) 
vinamidinium salt was synthesized from 3 eq of phosphorous oxychloride in dry DMF to which 
4'-chlorophenylacetic acid was slowly added. After refluxing for 3.5 hr., dH2O (100 mL) and NaClO4 
(20 g) was added to the rt solution. The resulting tan crystals (98%) were filtered and washed with 
20% NaClO4; 1H-NMR  δ = 7.73 (2H, s), 7.51 (2H, d, J = 8.5 Hz), 7.34 (2H, d, J = 8.5 Hz), 3.25, (6H, 
s), 2.46 (6H, s) ppm;  13C-NMR δ = 206.9, 206.6, 164.7, 135.5, 135.2, 132.7, 129.5, 105.5, 49.4, 40.4 
ppm. The title compound was synthesized from 2-(4'-chlorophenyl) vinamidinium salt, ethyl 
sarcosinate and NaH. To 4.4 eq of hexane-washed NaH in dry DMF under N2 (g) was added 1.5 eq of 
ethyl sarcosinate hydrochloride and the mixture was stirred for 15 min. at rt. Then the 2-(4'-
chlorophenyl) vinamidinium salt was added and the solution was stirred at rt for 45 min, then refluxed 
for 2.5 hr. The DMF was removed under reduced pressure. The crude pyrrole was taken up in EtOAc 
and washed with water (100 mL), then brine (100 mL). The product was purified by passing a solution 
of the pyrrole in CHCl3 through a short plug of silica gel followed by recrystallization from 
hexanes:EtOAc yielding a light yellow solid (100%); mp = 66-67oC; 1H-NMR  δ = 7.40 (2H, d, J = 8.5 
Hz), 7.29 (2H, d, J = 8.5 Hz), 7.18 (2H, d, J = 7 Hz), 7.03 (2H, d, J = 7 Hz), 4.31 (2H, q, J = 7.2 Hz), 
3.95 (3H, s), 1.37 (3H, t, J = 7.2 Hz) ppm; 13C-NMR δ = 161.20, 133.09, 131.61, 128.84, 126.26, 
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126.02, 123.69, 122.82, 114.64, 60.03, 37.00, 14.46 ppm. Anal calcd for C14H14ClNO2: C, 63.76; H, 
5.35; N, 5.31. Found: C, 63.68; H, 5.12; N, 5.09. 
 
Ethyl 2-(4’-Fluorophenacyl)-3-(4’-Fluorophenyl)-1H-pyrrole-4-carboxylate (7). Obtained from 2-
ammonium-4’-fluoroacetophenone toluenesulfonate (23i) and ethyl 3-(4'-fluorophenyl)-3-chloro-
propenal-2-carboxylate (20e) as a white solid (9%); mp = 141oC; 1H-NMR δ = 10.11 (1H, br s), 7.77 
(1H, d, J = 3.6 Hz), 7.37 (2H, d of d, JH,F = 5.5 Hz, JH,H = 9.8 Hz,), 7.05 (2H, d of d, JH,F = 5.3 Hz, JH,H 
= 9.6 Hz,) 6.77 (2H, t, J = 8.5 Hz), 6.74 (2H, t, J = 8.5 Hz), 4.18 (2H, q, J = 7.2 Hz), 1.20 (3H, t, J = 
7.2 Hz); 13C-NMR δ = 186.33, [166.30, 162.94 (d, JC,F = 254 Hz)], 163.67, [163.85, 160.57 (d, JC,F = 
247 Hz)], 133.20, 133.16, 132.82 (d, J2C,F = 8 Hz), 132.01, 131.45 (d, J2C,F = 9 Hz), 129.65, 128.90, 
114.70 (d, J3C,F = 22 Hz ppm), 114.13 , (d, J3C,F = 21 Hz), 60.06, 14.17 ppm; SFC/MS: (M+H)+ m/z 
356. Anal calcd for C20H15F2NO3: C, 67.60; H, 4.25; N, 3.94. Found: C, 67.56; H, 3.99; N, 3.91. 
 
Ethyl 2-(4’-Methoxyphenacyl)-3-(4’-Chlorophenyl)-1H-pyrrole-4-carboxylate (8). Obtained from 2-
ammonium-4’-methoxyacetophenone toluenesulfonate (23j) and ethyl 3-(4'-chlorophenyl)-3-chloro-
propenal-2-carboxylate (20a) as tan crystals (12%); mp = 105oC; 1H-NMR δ = 9.84 (1H, br s), 7.74 
(1H, d, J = 3.6 Hz), 7.34 (2H, d, J= 8.8 Hz), 7.04 (4H, s), 6.55 (2H, d, J = 8.8 Hz), 4.19 (2H, q, J = 
7.2 Hz), 1.22 (3H, t, J = 7.2 Hz); 13C-NMR δ = 186.36, 163.74, 162.61, 133.07, 132.56, 131.91, 
131.33, 130.93, 129.99, 129.25, 128.20, 127.24, 116.56, 112.94, 60.01, 55.45, 14.21 ppm; SFC/MS: 
(M+H)+ m/z  384; HRMS-CI calcd for C21H18ClNO4 (M+Na)+ m/z 406.0817 found 406.0811. 
 
Ethyl 2-(4’-Chlorophenacyl)-3-(4’-Fluorophenyl)-1H-pyrrole-4-carboxylate (9). Obtained from 2-
ammonium-4’-chloroacetophenone toluenesulfonate (23g) and ethyl 3-(4'-fluorophenyl)-3-chloro-
propenal-2-carboxylate (20e) as a tan solid (8%); mp = 133oC; 1H-NMR δ = 9.97 (1H, br s), 7.77 (1h, 
d, J = 3.6 Hz), 7.26 (2H, d, J = 8.8 Hz), 7.03 (4H, m), 6.77 (2H, t, J = 8.7 Hz), 4.18 (2H, q, J = 7.2 Hz), 
1.20 (3H, t, J = 7.2 Hz); 13C-NMR δ = 186.39, 163.60, [137.85, 135.33 (d, JC,F = 190 Hz)], 132.82, 
132.71, 132.16, 130.25, 129.59, 128.94, 128.84, 127.80, 116.97, 114.30, 114.01, 60.08, 14.16 ppm; 
SFC/MS: (M+H)+ m/z 372; HRMS-CI calcd for C20H15ClFNO3 (M+Na)+ m/z 394.0617 found 
394.0619.  
 
Methyl 2-(4’-Methylphenacyl)-3-(4’-methoxyphenyl)-1H-pyrrole-4-carboxylate (10). Obtained from 2-
ammonium-4’-methylacetophenone toluenesulfonate (23k) and methyl 3-(4'-methoxyphenyl)-3-
chloropropenal-2-carboxylate (20f) as tan crystals (11%); mp = 185-189oC; 1H-NMR δ = 10.10 (1H, br 
s), 7.81 (2H, d, J = 8 Hz), 7.65 (2H, d, J = 9 Hz), 7.37 (1H, d, J = 3.5 Hz), 7.31 (2H, d, J = 8 Hz), 
6.96 (2H, d, J = 9 Hz), 3.85 (3H, s), 3.77 (3H, s), 2.45 (3H, s); 13C-NMR δ = 184.53, 164.57, 160.56, 
143.08, 142.54, 134.91, 130.65, 129.73, 129.19, 128.76, 126.02, 122.83, 122.00, 113.77, 55.34, 51.24, 
21.66 ppm;  SFC/MS: (M+H)+ m/z 350; HRMS-CI calcd for C21H19NO4 (M+Na)+ m/z 372.1207 found 
372.1212. 
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Methyl 2-(4’-Methoxyphenacyl)-3-(4’-methoxyphenyl)-1H-pyrrole-4-carboxylate (11). Obtained from 
2-ammonium-4’-methoxyacetophenone toluenesulfonate (23j) and methyl 3-(4'-methoxyphenyl)-3-
chloropropenal-2-carboxylate (20f) as tan crystals (6%); mp = 166oC; 1H-NMR δ = 10.03 (1H, br s), 
7.71 (1H, d, J = 3.6 Hz), 7.37 (2H, d, J = 8.8 Hz), 7.03 (2H, d, J = 8.8 Hz), 6.61 (2H, d, J = 8.8 Hz), 
6.53 (2H, d, J = 8.8 Hz), 3.73 (3H, s), 3.72 (3H, s), 3.71 (3H, s); 13C-NMR δ = 186.71, 164.34, 162.34, 
158.83, 132.43, 132.31, 131.47, 129.92, 129.54, 128.34, 125.41, 116.01, 112.83, 112.79, 55.31, 55.18, 
51.08 ppm;  SFC/MS: (M+H)+ m/z 366. Anal calcd for C21H19NO5: C, 69.03; H, 5.24; N, 3.83. Found: 
C, 68.74; H, 4.98; N, 3.65. 
 
Methyl 2-(4’-Chlorophenacyl)-3-(4’-methoxyphenyl)-1H-pyrrole-4-carboxylate (12). Obtained from 2-
ammonium-4’-chloroacetophenone toluenesulfonate (23g) and methyl 3-(4'-methoxyphenyl)-3-chloro-
propenal-2-carboxylate (20f) as tan crystals (6%); mp = 189oC; 1H-NMR δ =  9.77 (1H, br s), 7.74 
(1H, d, J = 3.6 Hz), 7.24 (2H, d, J = 8.8 Hz), 7.00 (2H, d, J = 8.8 Hz), 6.96 (2H, d, J = 8.8 Hz), 6.59 
(2H, d, J = 8.8 Hz), 3.73 (3H, s), 3.72 (3H, s); 13C-NMR δ = 186.52, 164.07, 159.24, 137.36, 135.53, 
133.34, 132.32, 130.24, 129.59, 128.88, 127.67, 124.78, 116.47, 112.87, 55.33, 51.17 ppm;  SFC/MS: 
(M+H)+ m/z 370; HRMS-CI calcd for C20H16ClNO4 (M+Na)+ m/z 392.0660 found 392.0657. 
 
2-(4'-methoxyphenacyl)-3,4-bis(4'-methoxyphenyl)-1H-pyrrole (13) [3]. Obtained from 2-ammonium-
4’-methoxyacetophenone toluenesulfonate (23j) and 2,3-bis(4'-methoxyphenyl)-3-chloropropenal as 
tan crystals (93%); mp = 77-79oC; 1H-NMR δ = 9.45 (1H, br s), 7.40 (2H,d, J = 8.8 Hz), 7.15 (1H, d, J 
= 2.9 Hz), 7.00 (2H,d, J = 8.8 Hz), 6.80 (2H,d, J = 8.8 Hz), 6.75 (2H,d, J = 8.8 Hz), 6.54 (2H,d, J = 8.8 
Hz), 6.52 (2H,d, J = 8.8 Hz), 3.78 (3H, s), 3.72, (3H, s), 3.70 (3H, s); 13C-NMR δ = 186.7, 162.3, 
158.4, 132.6, 131.7, 130.6, 129.9, 129.6, 129.3, 127.4, 122.0, 113.9, 113.8, 113.5, 113.0, 55.4, 55.3 
ppm; HRMS-EI calcd for C26H24NO4 (M+) m/z 414.1705. Found 414.1693. 
 
Methyl 3,4-bis(3',4'-dimethoxyphenyl)-1H-pyrrole-2-carboxylate (14) [36]. Obtained from methyl 
glycinate hydrochloride, 2,3-bis(3',4'-dimethoxyphenyl)-3-chloropropenal and DABCO in toluene as 
tan crystals (92%); mp = 66-68oC; 1H-NMR δ = 3.58 (3H, s), 3.73 (3H, s), 3.75 (3H, s), 3.84 (3H, s), 
3.89 (3H, s), 6.57 (1H, br s), 6.74 (2H, br s), 6.83 (3H, br s), 7.08 (1H, d, J=3 Hz) and 9.16 (1H, broad 
s); 13C-NMR δ = 51.3, 55.5, 55.8, 55.9, 56.0, 110.6, 111.1, 111.9, 114.4, 119.4, 120.0, 120.3, 123.3, 
126.5, 126.9, 127.3, 129.0, 147.4, 148.0, 148.1, 148.4 and 161.6; FTIR (neat) 3320 and 1685 cm-1; 
HRMS-EI calcd for C22H23NO6 (M+) m/z 397.1525 found 397.1514. 
 
Ethyl N-Methyl 3,4-bis(3',4'-dimethoxyphenyl)-pyrrole-2-carboxylate (15). In a 250mL flask was 
placed 3’chloro-2’3’-bis-(3,4-dimethoxyphenyl)-2-propeneal (0.250g, 0.690mmol) and dry toluene 
(100mL). Once the solution became homogeneous, sarcosine ethyl ester hydrochloride (0.317g, 
2.07mmol) and DABCO (0.115g, 1.03mmol) was added.  The stirring solution was heated to reflux for 
24 hours under N2.  The reaction mixture was allowed to cool to room temperature and the organic 
layer was washed 3 times with water (50mL), once with brine (50mL), dried over Mg2SO4, filtered and 
concentrated in vacuo to give 310mg of a dark yellow brown oil which was purified by automated 
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flash chromatography (ethyl acetate/hexanes) by a slow gradient elution. An analytically pure sample 
was prepared by recrystalization from methanol/water to yield a yellow solid (114 mg, 38.9%); mp = 
143-144 oC; 1H-NMR δ = 6.93 (1H, s), 6.74-6.83 (4H, m), 6.72 (1H, s), 6.55 (1H, s), 4.09 (2H, q, J = 
7.2 Hz), 3.98 (3H, s), 3.88 (3H, s), 3.93 (3H, s), 3.75 (3H, s), 3.56 (3H, s), 1.01 (3H, t, J = 7.2 Hz); 
13C-NMR δ = 161.82, 148.37, 148.17, 147.82, 147.24, 130.52, 128.87, 127.41, 126.26, 123.85, 123.09, 
120.70, 119.86, 114.38, 111.64, 111.08, 110.59, 59.66, 55.95, 55.87, 55.82, 55.44, 37.54, 13.93; FT-IR 
(neat) 3110 cm-1, 2924 cm-1, 2831 cm-1, 1689 cm-1, 1413 cm-1, 1227 cm-1; HRMS-EI calc for 
C24H27NO6 (M+) m/z 425.1838 found 425.1859. 
 
Hypolipidemic Studies.  
 
CF-1 male mice and Sprague-Dawley male were purchased from Harlan (Indianapolis, IN) and 
acclimated to their new environment for at least 14 days prior to the start of any studies. Animals were 
housed in 12 h light-dark cycles at 68°F. Food (5015 mouse diet or 5012 rat diet, PMI Nutrition 
International) and water were given ad libitum. Healthy CF-1 male mice (~35 g) were administered 
I.P. 2-8 mg/kg of the pyrrole derivatives 3-15, 90 mg/kg/day of gemfibrozil (Teva), 8 mg/kg/day of 
atorvastatin (Pfizer), or 12.5 mg/kg/day of niacin (Sigma) dissolved in 1% CMC daily for 14 days. 
These dosage levels represent the therapuetic doses for the known drugs. The pyrroles were 
administered at the dosage range of the statins. Blood (~0.5 mL) was collected on day 7 from the 
suborbital vein under CO2 anesthesia. The mice were euthanatized with CO2 after 14 days upon 
completion of the study.  
Healthy Sprague-Dawley male rats (~400 g) were administered by gavage 2 mg/kg of the pyrrole 
derivatives 1 or 2, 90 mg/kg/day of gemfibrozil (Teva), or 8 mg/kg/day of atorvastatin (Pfizer) 
dissolved in 1% CMC daily for 14 days. Blood (~0.5mL) was collected on day 7 from the suborbital 
vein under CO2 anesthesia. Blood (~10 mL) was collected from the abdominal vein of pentobarbital-
anesthetized drug-treated Sprague-Dawley rats. The rats were euthanatized with pentobarbital-KCl I.P. 
after 14 days upon completion of the study. Body weights, organ weights and daily food consumption 
of rats were determined as previously reported [22].  
Serum was separated by centrifugation at 5000 rpm x 3 min. Total serum cholesterol (InfinityR), 
triglyceride (InfinityR), HDL-cholesterol (HDL-C PlusR) and LDL-cholesterol (LDL-C PlusR) 
concentrations were determined by commercial enzymatic assays (ThermoDMA, Louisville, CO) and 
analyzed on a Perkin-Elmer λ-25 UV-Vis spectrometer.  
Rat liver, small intestine, and fecal materials (24 h collection) were removed and lipids extracted 
[37].  To 2 mL of a 10% tissue homogenate in 10% sucrose/1mM EDTA was added 6 mL of 1:2 
CHCl3:CH3OH, then mixed via a vortex for 30 sec. and let stand for few minutes. An additional 2 mL 
of CHCl3 was added to each tube and vortexed for 30 sec. The CHCl3 layer was removed and allowed 
to evaporate yielding the lipid residue. The lipid residue was dissolved in 200 µL of CHCl3. The total 
cholesterol and triglyceride concentrations of the lipid extracts were determined as described above.  
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Statistical Analysis.  
 
Data is displayed in tables and figures as the means ± standard deviations of the mean expressed as 
a percentage of the control value. N is the number of samples per group. The Student’s “t”-test was 
used to determine the probable level of significance (p) between test samples and control samples. 
Values of p < 0.05 were considered to be significant. 
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